ArticleHemaSphere2024

New therapies for relapsed or refractory aggressive B-cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group.

Mariana Bastos-Oreiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.